Over the next few years, we will integrate within the Company all of the components that are required to design and develop our own therapeutic drug candidates.
This will require building additional expertise in computational and medicinal chemistry as well as the capability to generate humanized antibodies.
Furthermore, we will incorporate a group of biologists to enable preclinical testing in animal models. Our plan includes expanding the development of our capabilities to retain intellectual property around our proprietary therapeutic compounds since this will bring the greatest value to the Company.